MGMT and glioblastoma: A phase III CENTRIC trial and a phase II CORE trial both in completed state and investigated that Cilengitide failed to improve progression-free survival (PFS) and overall survival (OS) for glioblastoma patients without MGMT methylation, which precludes its clinical utilization (Li et al., 2019; Liu et al., 2023b).